apo-tamox 10 mg comprimate
apotex inc. - tamoxifenum - comprimate - 10 mg
apo-tamox 20 mg comprimate
apotex inc. - tamoxifenum - comprimate - 20 mg
tamoxifen comprimate 20 mg
naprod life sciences pvt. ltd. - tamoxifenum - comprimate - 20 mg
tamoximed comprimate 10 mg
balkan pharmaceuticals srl, sc - tamoxifenum - comprimate - 10 mg
tamoximed comprimate 20 mg
balkan pharmaceuticals srl, sc - tamoxifenum - comprimate - 20 mg
zitazonium comprimate 10 mg
egis pharmaceuticals plc - tamoxifenum - comprimate - 10 mg
tamoxifen 20 mg comprimate filmate
sandoz pharmaceuticals d.d. - tamoxifenum - comprimate filmate - 20 mg
orserdu
stemline therapeutics b.v. - elacestrant - sânii neoplasme - terapia endocrină - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
fareston
orion corporation - toremifen - sânii neoplasme - terapia endocrină - tratamentul cu hormoni de primă linie pentru cancerul de sân metastatic dependent de hormoni la pacienții în postmenopauză. fareston nu este recomandat pentru pacienții cu receptori estrogenici negativi tumori.
faslodex
astrazeneca ab - fulvestrant - sânii neoplasme - terapia endocrină, anti-estrogeni - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. În pre - sau femeile în pre-menopauză, tratament combinat cu palbociclib ar trebui să fie combinate cu un hormon luteinizant hormonului de eliberare (lhrh) agonist.